ArticleNuclear medicine communications2025
Correlation study of 18F-FDG PET/CT metabolic parameters, heterogeneity index, and microvascular invasion, and its nomogram potential in predicting microvascular invasion in liver cancer before liver transplantation.
Article in Nuclear medicine communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a highly prevalent malignant tumor worldwide, with Chinese patients accounting for more than 50%. Microvascular invasion (MVI) is a significant risk factor for postoperative recurrence of HCC. 18 F-fluorodeoxyglucose PET/computed tomography ( 18 F-FDG PET/CT), as a hybrid imaging modality integrating metabolic information from PET with anatomical details from CT. This combined approach enables simultaneous assessment of glucose metabolism and structural features. It can also evaluate tumor biological behavior through metabolic parameters and heterogeneity characteristics.
objectiveTo explore the predictive value of 18 F-FDG PET/CT metabolic parameters and heterogeneity index for MVI in HCC patients before liver transplantation and to construct a nomogram prediction model.
methodsA retrospective study involving 177 HCC patients who underwent liver transplantation (100 MVI-positive cases and 77 MVI-negative cases) was conducted to analyze the correlation between clinical characteristics, PET/CT metabolic parameters (SUVmax, SUVmean, TLG, and TLR), and heterogeneity parameters (COV and HI) with MVI. Independent predictors were identified using univariate and multivariate logistic regression, and a nomogram model was constructed. The model's performance was evaluated using calibration curves and ROC curves.
resultsUnivariate analysis showed significant differences in PIVKA-II, SUVmax, TLG, TLR, COV, and HI between the two groups (all P < 0.05). Multivariate analysis indicated that PIVKA-II (OR = 1.000, P = 0.042), TLG (OR = 0.999, P = 0.024), HI (OR = 1.022, P < 0.001), and TLR (OR = 1.618, P = 0.031) were independent predictors of MVI. The area under the ROC curve (AUC) of the combined model reached 0.815 (95% confidence interval: 0.754-0.876), significantly better than any single parameter. The nomogram calibration curve showed a high consistency between predicted probabilities and actual observed probabilities (mean absolute error = 0.025).
conclusionThe integration of PET/CT-derived parameters-specifically TLG (metabolic burden), HI (heterogeneity), and TLR (tumor-to-liver contrast)-with serum PIVKA-II provides a robust tool for preoperative MVI prediction in HCC patients undergoing liver transplantation. The validated nomogram model (AUC = 0.815) outperforms individual parameters, offering a reliable basis for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.